Medistim ASA

As of June 30, 2026, Medistim ASA carries a market capitalization of 4.11B, placing it among publicly traded companies globally. Its enterprise value stands at 4.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medistim ASA's next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, Medistim ASA has 18.28M shares outstanding.

As of June 30, 2026, Medistim ASA trades at a trailing price-to-earnings ratio of 23.69. The price-to-sales ratio is 5.45, and the price-to-book ratio stands at 10.01.

As of June 30, 2026, Medistim ASA trades at an EV/EBITDA multiple of 17.80 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.36 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.50 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Medistim ASA trades at an EV/FCF ratio of 25.46, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 4.05B versus a market cap of 4.11B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Medistim ASA maintains a current ratio of 3.15, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.46, indicating elevated leverage, while an interest coverage ratio of 571.29 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Medistim ASA posted a return on equity (ROE) of 39.56, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 36.04 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 28.95, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 37.06, useful for judging operating efficiency across full business cycles. The company generates approximately 4.79M in revenue per employee across its workforce of 157.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.89 indicates how many times Medistim ASA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Medistim ASA recorded 51.06M in income tax expense. That works out to an effective tax rate of 22.73, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 224.63M, leaving 173.57M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Medistim ASA's stock has gained approximately 25.99% over the past 52 weeks. The 50-day moving average sits at 246.72, while the 200-day moving average is 229.62.

Over the twelve months ended June 30, 2026, Medistim ASA generated 755.07M in revenue and converted that into 173.57M in net income, yielding earnings per share of 9.50. EBITDA reached 227.37M, while operating income came in at 218.82M.

As of June 30, 2026, Medistim ASA holds 100.15M in cash and equivalents against 34.79M in total debt, resulting in a net debt position of -100.15M. Total book value stands at 411.01M, with working capital of 264.50M providing operational flexibility.

Medistim ASA produced 158.71M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Medistim ASA posted a gross margin of 80.94, reflecting its pricing power and cost economics. The operating margin of 28.98 and net profit margin of 22.99 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Medistim ASA paid dividends of 14.02 per share. The dividend payout ratio of 147.62 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.86, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.40, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Medistim ASA shareholders.